[NCI CIRB] NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy with or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (PROMETHEAN)

Principal Investigator

Arthur Hung

Study Purpose

This phase II trial tests whether relugolix (the study drug) and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (called "oligometastatic"). Testosterone can cause the growth of prostate cancer cells. The study drug lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Giving the study drug with radiation therapy may help lower the chance of prostate cancer growing or spreading.

Medical Condition(s)

Prostate Cancer

Eligibility Criteria

Pathologically proven diagnosis of prostate adenocarcinoma at any anatomical location (for example, prostate, metastatic site), including intraductal or ductal carcinoma.

Age >= 18 years

Age Range

18 - 99

Healthy Volunteers Needed


Duration of Participation

Up to 5 years

Minors Included



Knight Cancer Institute Clinical Trials,, 503-494-1080


Recruitment End


Compensation Provided


Go Back